Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.
How this was made
The 30-second read
Why it matters
The earnings release highlights a cash increase and product launch, which may attract short‑term buying interest.
Market read
First‑time commercial availability of a novel therapy could drive REPL stock higher, with broader biotech sector uplift.
What to watch
Potential reimbursement challenges and competition from other melanoma therapies.
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
TUDRIQEV entered commercial availability and management reported early account engagement and prescribing activity, while the company remained pre-revenue in the reported statements and recorded a GAAP net loss of $ (57,121) (in thousands).
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expense, three months ended September 30 (Amounts in thousands)GAAP | $34.37M | – | – |
| Selling, general and administrative expense, three months ended September 30 (Amounts in thousands)GAAP | 21.92M | – | – |
| Total operating expenses, three months ended September 30 (Amounts in thousands)GAAP | 56.28M | – | – |
| Loss from operations, three months ended September 30 (Amounts in thousands)GAAP | −56.28M | – | – |
| Research and development incentives, three months ended September 30 (Amounts in thousands)GAAP | 238K | – | – |
| Investment income, three months ended September 30 (Amounts in thousands)GAAP | 1.88M | – | – |
| Interest expense on finance lease liability, three months ended September 30 (Amounts in thousands)GAAP | −502K | – | – |
| Interest expense on debt obligations, three months ended September 30 (Amounts in thousands)GAAP | −2.52M | – | – |
| Other income (expense), net, three months ended September 30 (Amounts in thousands)GAAP | 67K | – | – |
| Total other (expense) income, net, three months ended September 30 (Amounts in thousands)GAAP | −840K | – | – |
| Net loss, three months ended September 30 (Amounts in thousands)GAAP | −$57.12M | – | – |
| Net loss per common share, basic and diluted, three months ended September 30GAAP | $ (0.54 ) | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended September 30other | 105,176,101 | – | – |
| Research and development expense, six months ended September 30 (Amounts in thousands)GAAP | $83.64M | – | – |
| Selling, general and administrative expense, six months ended September 30 (Amounts in thousands)GAAP | 40.88M | – | – |
| Total operating expenses, six months ended September 30 (Amounts in thousands)GAAP | 124.5M | – | – |
| Loss from operations, six months ended September 30 (Amounts in thousands)GAAP | −124.5M | – | – |
| Research and development incentives, six months ended September 30 (Amounts in thousands)GAAP | 534K | – | – |
| Investment income, six months ended September 30 (Amounts in thousands)GAAP | 3.84M | – | – |
| Interest expense on finance lease liability, six months ended September 30 (Amounts in thousands)GAAP | −1.01M | – | – |
| Interest expense on debt obligations, six months ended September 30 (Amounts in thousands)GAAP | −5.10M | – | – |
| Other income (expense), net, six months ended September 30 (Amounts in thousands)GAAP | −621K | – | – |
| Total other (expense) income, net, six months ended September 30 (Amounts in thousands)GAAP | −2.36M | – | – |
| Net loss, six months ended September 30 (Amounts in thousands)GAAP | −$126.9M | – | – |
| Net loss per common share, basic and diluted, six months ended September 30GAAP | $ (1.26 ) | – | – |
| Weighted average common shares outstanding, basic and diluted, six months ended September 30other | 101,042,985 | – | – |
| Research and development stock-based compensation expense, fiscal second quarter ended September 30, 2026GAAP | $4.9M | – | – |
| Selling, general and administrative stock-based compensation expense, fiscal second quarter ended September 30, 2026GAAP | $5.7M | – | – |
| Cash, cash equivalents and short-term investments, September 30, 2026 (in thousands)GAAP | $307.8M | – | – |
| Working capital, September 30, 2026 (in thousands)GAAP | 278.5M | – | – |
| Total assets, September 30, 2026 (in thousands)GAAP | 373.9M | – | – |
| Total stockholders' equity, September 30, 2026 (in thousands)GAAP | 204.8M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
From the issuance of the condensed consolidated financial statements outlook
- NoteExisting cash and cash equivalents will enable the Company to fund operations for greater than twelve months, including the commercialization of TUDRIQEV in advanced melanoma and for working capital and general corporate purposes.
What drove it
- TUDRIQEV was first delivered to patients for advanced melanoma on October 6th.
- More than 15 institutions have prescribed TUDRIQEV.
- The company actively engaged with more than 70 percent of its initial 200 priority accounts to establish workflows and enable adoption.
- Leading melanoma institutions placed TUDRIQEV on formulary and started treating patients.
- Management attributed the lower research and development expense to decreases in personnel-related and other costs and direct research costs relating to the IGNYTE, ARTACUS and CERPASS studies.
- IGNYTE-3 and the registration-directed REVEAL study remain actively enrolling.
Concerns
- No revenue was reported in the condensed consolidated statements of operations.
- TUDRIQEV's indication is approved under accelerated approval based on objective response rate and duration of response; continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s).
- The company reported a GAAP net loss of $ (57,121) (in thousands) for the three months ended September 30, 2026.
- Interest expense on debt obligations was (2,523 ) (in thousands) for the three months ended September 30, 2026.
- The company cited limited commercialization experience, confirmatory-trial execution, manufacturing, reimbursement and utilization among risks.
What to watch
- TUDRIQEV ordering, formulary placement, payer-policy coverage and patient treatment progress following commercial availability.
- Enrollment and future results from IGNYTE-3, whose primary endpoint is overall survival.
- Enrollment and future results from the REVEAL Phase 2/3 trial of RP2 in metastatic uveal melanoma.
- Cash burn related to operating activities, commercialization spending and the stated greater-than-twelve-month cash runway.
- Execution against the company's product manufacturing goal and availability of combination therapies needed for clinical trials.
Balance sheet and cash flow
- Cash, cash equivalents and short-term investments were $ 307,833 (in thousands) as of September 30, 2026, compared with $ 268,889 (in thousands) as of March 31, 2026.
- The company reported approximately net $141.0 million in proceeds from its August 2026 offering of common stock and pre-funded warrants.
- The company received $15.0 million in proceeds from long-term debt from the initial draw down on tranche 4 in September 2026.
- Working capital was 278,482 (in thousands), total assets were 373,940 (in thousands), and total stockholders' equity was 204,778 (in thousands) as of September 30, 2026.
Analysis
Replimune reported its fiscal second quarter ended September 30, 2026 as it began the commercial launch of TUDRIQEV. The company said healthcare providers began ordering the product for next-day delivery immediately upon availability, that more than 15 institutions have prescribed it, and that it had engaged with more than 70 percent of its initial 200 priority accounts. These are early launch activity indicators rather than reported sales, as the condensed consolidated statements of operations contain no revenue line.
The expense base was lower than the prior-year quarter on the reported GAAP lines. Research and development expense was $ 34,365 (in thousands), compared with $ 57,877, and selling, general and administrative expense was 21,916, compared with 26,414. Management attributed the research and development reduction to lower personnel-related and other costs and lower direct research costs related to the IGNYTE, ARTACUS and CERPASS studies. The lower operating expense base corresponded with a net loss of $ (57,121) (in thousands), compared with $ (83,100).
Liquidity increased during the period. Cash, cash equivalents and short-term investments were $ 307,833 (in thousands) at September 30, 2026, versus $ 268,889 at March 31, 2026. Management attributed the increase to approximately net $141.0 million from the August offering of common stock and pre-funded warrants and $15.0 million from the tranche 4 debt draw, partly offset by operating cash burn. The company expects existing cash and cash equivalents to fund operations for greater than twelve months from issuance of the condensed consolidated financial statements.
The strategic focus remains commercial execution for TUDRIQEV alongside pivotal and registration-directed development work. IGNYTE-3 is actively enrolling with overall survival as its primary endpoint, while the REVEAL Phase 2/3 study of RP2 is also actively enrolling. Continued approval of TUDRIQEV may be contingent on confirmatory verification of clinical benefit, making execution of IGNYTE-3, launch uptake, payer coverage and manufacturing progress central reported watch items.
Management, verbatim
The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.
Sushil Patel, Ph.D., CEO of Replimune
Not in the filing
stated, not guessed- Revenue and revenue comparisons
- Segment revenue and segment comparisons
- Gross profit and gross margin
- Operating income as a positive metric; the company reported loss from operations
- Non-GAAP financial metrics, including non-GAAP EPS
- Operating cash flow
- Free cash flow
- Cash flow statement
- Debt balance
- Share repurchases
- Dividends
- Prior-quarter comparative figures for the three-month operating-results metrics
- Explicit percentage year-over-year or sequential changes for reported financial-statement metrics
- The previous outlook contained no guidance for a reported metric in this quarter, only liquidity and timing statements that do not match any reported figure.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Replimune's TUDRIQEV is the first oncolytic virus approved for advanced melanoma in the US, marking a milestone for the company.
Ticker impact
Replimune disclosed its Q2 2027 financial results, launch of TUDRIQEV for advanced melanoma, and a cash balance of $307.8M.
likely upward pressure as investors price in commercial availability of TUDRIQEV and strong cash position
New revenue potential from the first oncolytic therapy launch and a sizable cash buffer reduce near‑term risk.
Market effects
Boosts biotech sector sentiment around oncolytic immunotherapy advances.
Positive for US biotech listings, modest effect on broader market.
Limited to investors tracking oncology drug pipelines.
Counterpoint
If sales uptake is slower than expected, the stock could face pressure despite cash strength.
Key entities
- companyReplimune Group, Inc.
Biotech firm developing oncolytic immunotherapies.
- productTUDRIQEV
Oncolytic viral therapy for advanced melanoma.


